Across TCGA pan-cancer cohorts, TMEM231 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM231 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TMEM231 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM231 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

UCEC, LUAD, and GBM are the cancer types where TMEM231 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.249	1.000	.002	50	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	9	view →
GBM	OS	Tertile	All	0.657	0.443	.008	5	view →
LSCC	DFS	Tertile	II,III,IV	0.898	1.000	.041	1	view →
PDAC	OS	Median	All	0.810	0.979	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TMEM231 tumor-vs-normal RNA expression · all TMEM231 data types